PL365744A1 - Methods of drug delivery to hepatocytes and treatment of flaviviridae infections - Google Patents

Methods of drug delivery to hepatocytes and treatment of flaviviridae infections

Info

Publication number
PL365744A1
PL365744A1 PL01365744A PL36574401A PL365744A1 PL 365744 A1 PL365744 A1 PL 365744A1 PL 01365744 A PL01365744 A PL 01365744A PL 36574401 A PL36574401 A PL 36574401A PL 365744 A1 PL365744 A1 PL 365744A1
Authority
PL
Poland
Prior art keywords
hepatocytes
treatment
methods
drug delivery
flaviviridae infections
Prior art date
Application number
PL01365744A
Other languages
Polish (pl)
Inventor
Johnson Lau
Zhi Hong
Original Assignee
Ribapharm Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribapharm Inc. filed Critical Ribapharm Inc.
Publication of PL365744A1 publication Critical patent/PL365744A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL01365744A 2000-08-22 2001-08-21 Methods of drug delivery to hepatocytes and treatment of flaviviridae infections PL365744A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22686900P 2000-08-22 2000-08-22
US24062700P 2000-10-13 2000-10-13

Publications (1)

Publication Number Publication Date
PL365744A1 true PL365744A1 (en) 2005-01-10

Family

ID=26920944

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01365744A PL365744A1 (en) 2000-08-22 2001-08-21 Methods of drug delivery to hepatocytes and treatment of flaviviridae infections

Country Status (15)

Country Link
EP (1) EP1313469A1 (en)
JP (1) JP2004506684A (en)
KR (1) KR20030040416A (en)
CN (1) CN1447692A (en)
AU (1) AU2001292557A1 (en)
BR (1) BR0113388A (en)
CA (1) CA2415793A1 (en)
CZ (1) CZ2003308A3 (en)
HU (1) HUP0302884A2 (en)
IL (1) IL154167A0 (en)
MX (1) MXPA03001529A (en)
NO (1) NO20030794L (en)
PL (1) PL365744A1 (en)
RU (1) RU2003102607A (en)
WO (1) WO2002015904A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037908A1 (en) * 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
US7608258B2 (en) 2002-04-13 2009-10-27 Allan Mishra Method for treatment of tendinosis using platelet rich plasma
US6811777B2 (en) * 2002-04-13 2004-11-02 Allan Mishra Compositions and minimally invasive methods for treating incomplete connective tissue repair
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
WO2010042658A1 (en) 2008-10-07 2010-04-15 Bioparadox, Llc Use of platelet rich plasma composition in the treatment of cardiac conduction abnormalities
US20140356893A1 (en) 2013-06-04 2014-12-04 Allan Mishra Compositions and methods for using platelet-rich plasma for drug discovery, cell nuclear reprogramming, proliferation or differentiation
CA2937548C (en) 2014-02-13 2022-10-25 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
JP2017520545A (en) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド Prodrug compounds and their use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984396A (en) * 1971-06-01 1976-10-05 Icn Pharmaceuticals, Inc. 1-(β,-D-ribofuranosyl)-1,2,4-triazole acid esters
US5959077A (en) * 1993-05-26 1999-09-28 Laboratori Balducci S.P.A. Hepatotropic conjugates of antiviral drugs carriers thereof and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CA2415793A1 (en) 2002-02-28
EP1313469A1 (en) 2003-05-28
KR20030040416A (en) 2003-05-22
JP2004506684A (en) 2004-03-04
CN1447692A (en) 2003-10-08
AU2001292557A1 (en) 2002-03-04
IL154167A0 (en) 2003-07-31
NO20030794D0 (en) 2003-02-20
BR0113388A (en) 2004-02-25
WO2002015904B1 (en) 2002-07-04
RU2003102607A (en) 2004-07-27
MXPA03001529A (en) 2004-04-02
NO20030794L (en) 2003-04-22
CZ2003308A3 (en) 2004-03-17
WO2002015904A1 (en) 2002-02-28
HUP0302884A2 (en) 2003-12-29

Similar Documents

Publication Publication Date Title
HUP0301121A3 (en) Topical pharmaceutical formulations and methods of treatment
PL372925A1 (en) Prevention and treatment of restenosis by local administration of drug
IL215891A (en) Hepatitis c virus serine protease inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment of hepatitis c virus infections
HUP0500003A3 (en) Improvements in and relating to medicament injection apparatus
GB2412318B (en) Drug delivery particles and methods of treating particles to improve their drug delivery capabilities
EP1231864A4 (en) Drug delivery catheters that attach to tissue and methods for their use
EE05149B1 (en) Biar acarboxamides, process for their preparation, pharmaceutical composition containing them and their use in therapy
DK1183029T3 (en) Pharmaceutical preparation containing diamorphine and vitamin E and its use in the treatment of opiate abuse
EP1689348A4 (en) Oligosaccharide compositions and use thereof in the treatment of infection
HUP0300746A3 (en) Proline derivatives and use thereof as drugs
MXPA02004770A (en) Therapeutic compositions and methods of use thereof.
HUP0301892A3 (en) Pharmaceutical compositions for treatment of sexual dysfunction and their preparation
IL160754A0 (en) Dosage form, device and methods of treatment
EE200200271A (en) Combinations of medicinal products and their use
IL154167A0 (en) Methods of drug delivery to hepatocytes and treatment of flaviviridae infections
EP1356812A4 (en) Medicines for treatment and prevention of neurogenic pain
EP1491210A4 (en) Therapeutic drug using antibody-presenting hollow protein nanoparticles and hollow protein nanoparticles
GB9912639D0 (en) Improvements in and relating to treatment of respiratory conditions
EP1337265A4 (en) Methods of treatment comprising administration of substance p
GB0003201D0 (en) Method to potentiate the therapeutic efficacy of taxane and derivatives thereof
EP1666046A4 (en) Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis
HUP0301119A3 (en) Biologically active agent and drug
AU2002322424A8 (en) Novel methods and formulations for administration of active agents
GB0007788D0 (en) Method to evaluate the therapeutic and toxic effects related to drug administration
GB0120124D0 (en) Effect of timing and duration of administration of amp 579 on reperfusion injury in rabbit heart

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)